The treatment of MDD patients with selective serotonin reuptake inhibitors (SSRIs) reduces IL-6 and TNF-α levels, and their antidepressant therapeutic effects may be partly attributed to their anti-inflammatory properties (55). The gene discussed is IL6; the disease is major depressive disorder.